Base-case estimated number of patients categorised in different phenotypes and age groups and their base-case cost of management. by Siew Chin Ong (9314213)

Base-case results based on evidence from randomized controlled trials (means and ranges). The comparator is no intervention. by Afschin Gandjour (342184)

Base-case results (deterministic analysis). by Robert Hodgson (2026294)

Base-case results: Probabilistic analysis. by Robert Hodgson (2026294)

Significant demographic factors associated with the usefulness of an early warning to take timely preventive action. by Rafdzah Zaki (161810)

Significantly Enriched Pathways. by Jiyong Zhang (2498740)

“…By comparing samples from NAFLD patients and healthy controls, we identified 1,770 significant DEGs, with 1,073 being upregulated and 697 downregulated. …”

Gene specific primers used for <i>GmNN1/FT2a</i> fine mapping. by Xinxin Li (281237)

Base-case results. by Mingxi Xie (19812594)

“…Clinical findings have showed that deprescribing service significantly decreased inappropriate PPIs utilization. …”

Base-case results. by Ping Chen (89712)

The base case analysis. by Wenwang Lang (20293527)

“…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …”

Base-case results. by Shuo Kang (1306860)

“…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …”

Base-case analysis. by Akiko Kowada (14659965)

“…The willingness-to-pay (WTP) threshold was set at US$50,000 per QALY gained. In the base-case analysis, HTLV-1 antenatal screening (US$76.85, 24.94766 QALYs, 24.94813 LYs, ICER; US$40,100 per QALY gained) was cost-effective compared with no screening (US$2.18, 24.94580 QALYs, 24.94807 LYs). …”

Characterization and outcomes of lymphoma cases based on immunophenotype. by Heather Wilson-Robles (731578)

Distribution of proven CPA cases based on their types. by Aishwarya Selvasekhar (20529339)

The MDAE does not vary significantly for different sizes of subsampled graphs. by Niklas Smedemark-Margulies (3539957)

Statistically significant DMRs (<i>fwerArea</i> ≤ 0.05) between severe and mild SS cases located in genes previously identified as hypomethylated in cases relative to non-cases. by Calvin Chi (6240473)

Significant factors in Section A associated with the usefulness of an early warning to take timely preventive action. by Rafdzah Zaki (161810)

Temporal profiles of the key BO-NN features. by Julia Berezutskaya (9080269)

“…The shifts associated with non-significant prediction accuracies are greyed-out. <b>(c)</b> The results of the MDS for the key BO-NN features. …”

This is the data set that we used to reach the conclusions drawn in the manuscript with related metadata and methods. by Farayi Kaseke (19560197)

Phenotype and molecular identification of <i>GmNN1/FT2a</i> in stable transgenic soybean plants. by Xinxin Li (281237)